Table 1.

Characteristics of eligible studies considered in this meta-analysis.

Study	Year	Type of study	Regimen		Number of patients		Hematological adverse events
			Platinum	Control	Platinum	Control	Anemia	Neutropenia	Thrombocytopenia	Febrile neutropenia
Aguilar Martinez et al.17	2015	RCT	Cis + P→Cis + Dox	P → FAC	30	31	No	No	No	No
Alba et al.8	2012	RCT	EC→DCb	EC→D	48	46	Yes	Yes	Yes	Yes
Ando et al.18	2014	RCT	PCb→CEF	P→CEF	37	38	No	No	No	No
Loibl et al.15	2018	Subgroup in RCT	PCb→AC	P→AC	160	158	Yes	Yes	Yes	Yes
Schneeweiss et al.9	2019	RCT	PM(Cb)	iddEPC	203	200	No	No	No	No
Sikov et al.16	2015	Subgroup in RCT	wPCb→ddAC	wP→ddAC	113	108	No	Yes	Yes	Yes
Zhang et al.10	2016	RCT	PC	EP	47	44	No	Yes	Yes	No
Zhao et al.19	2014	RCT	TC	TE	38	44	Yes	Yes	Yes	No

A, adriamycin; C, cyclophosphamide; Cb, carboplatin; Cis, cisplatin; D, docetaxel; Dox, doxorubicin; E, epirubicin; M, non-pegylated liposomal doxorubicin; P, paclitaxel; RCT, randomized controlled trial; T, taxol; wP, weekly paclitaxel; idd, intense dose-dense.